Abstract
Abstract Angiopoietin like (ANGPTL) proteins are secreted proteins showing structural similarity to members of the angiopoietin family. Some ANGPTL proteins possess pleiotropic activities, being involved in cancer lipid, glucose energy metabolisms and angiogenesis. ANGPTL7 is the less characterized member of the family whose functional role is only marginally known. In this study we provide experimental evidences that ANGPTL7 is over-expressed in different human cancers. To understand the role played by ANGPTL7 in tumor biology, we asked whether ANGPTL7 is endogenously expressed by malignant cells or in response to environmental stimuli. We found that ANGPTL7 is marginally expressed under standard growth condition while it is specifically up-regulated by hypoxia. The regulatory mechanism underlining the ANGPTL7 response to hypoxia need to be elucidated. Interestingly, the protein is secreted and partially associated with the exosomial fraction, suggesting that it could be found in the systemic circulation of oncologic patients and act in an endocrine way. Moreover we found that ANGPTL7 exerts a pro-angiogenetic effect on human differentiated endothelial cells by stimulating their motility, invasiveness and capability to form capillary-like networks while it does not stimulate bone marrow derived progenitor endothelial cells. Finally, we showed that ANGPTL7 promotes vascularization in vivo in the mouse matrigel sponge assay, thereby accrediting this molecule as a pro-angiogenic factor. This suggests that ANGPTL7 could be an attractive therapeutic target for anti-angiogenic tumor therapy. Citation Information: Mol Cancer Ther 2013;12(11 Suppl):B7. Citation Format: Matteo Parri, Laura Pietrovito, Alberto Grandi, susanna campagnoli, Piero Pileri, Elisa De Camilli, Laura Bianchini, Guido Grandi, Giuseppe Viale, Paola Chiarugi, Renata Maria Grifantini. Angiopoietin like 7, a novel pro-angiogenetic factor over-expressed in cancer. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2013 Oct 19-23; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2013;12(11 Suppl):Abstract nr B7.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
